Genomic Testing

The scope can range from targeted panels to exome or whole-genome sequencing. A targeted test looks only at specified regions, while broader sequencing generates far more data and may still leave some variant types difficult to detect. Collection, sequencing platform, coverage, quality thresholds, and bioinformatic pipeline shape what can be reported.

A result may classify variants according to available evidence, but classification can change as shared knowledge and databases develop. Some findings have uncertain significance, and the absence of a reported variant does not mean every genetic contribution has been excluded. Family relationships and ancestry composition can also affect interpretation.

Genomic testing differs from epigenetic testing: sequence analysis reads DNA letters, while methylation analysis examines chemical marks associated with regulation. Pharmacogenomics is a more focused use of genetic information related to medication response. The test purpose and consent process should be clear before a broad report is treated as useful context.

Privacy and family implications are distinctive features of genomic information. A result can indirectly reveal information relevant to biological relatives, and raw data may be reusable beyond the original question. Storage, access, secondary findings, and data-sharing policies are practical parts of informed interpretation.

Different variant classes require different detection methods. A test that reliably identifies single-letter substitutions may have different sensitivity for repeat expansions, large structural rearrangements, copy-number changes, or variants in technically difficult genomic regions.

Related Previvo services: Longevity Genomic Testing Winnipeg | Previvo, Comprehensive Genetic Testing | Previvo.